VERTEX PHARMACEUTICALS INC / MA Inventory Write-down
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Inventory Write-down of $8.65 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-10-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2019-10-31
- VERTEX PHARMACEUTICALS INC / MA inventory write-down for the quarter ending 2019-09-30 was $1.61M, a 73.90% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA inventory write-down for the quarter ending 2019-06-30 was $5.77M, a 74.43% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA inventory write-down for the quarter ending 2019-03-31 was $1.27M, a 64.91% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA inventory write-down for the quarter ending 2018-12-31 was $7.32M, a 76.31% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA inventory write-down for fiscal 2018 was $20.41M, a 33.49% increase from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA inventory write-down for fiscal 2017 was $15.29M.
- VERTEX PHARMACEUTICALS INC / MA inventory write-down for fiscal 2016 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA inventory write-down for fiscal 2015 was $0.00.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2019-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $7.38M derived: sum of 2 quarters · filed 2019-10-31 | $8.65M 10-Q · filed 2019-10-31 | $15.97M derived: sum of 4 quarters · filed 2019-10-31 |
| 2019-06-30 | $5.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $7.04M 10-Q · filed 2019-08-01 | $14.37M derived: sum of 3 quarters · filed 2019-08-01 | $20.53M derived: sum of 4 quarters · filed 2019-10-31 |
| 2019-03-31 | $1.27M 10-Q · filed 2019-05-01 | $8.59M derived: sum of 2 quarters · filed 2019-05-01 | $14.76M derived: sum of 3 quarters · filed 2019-10-31 | $18.06M derived: sum of 4 quarters · filed 2019-10-31 |
| 2018-12-31 | $7.32M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $13.48M derived: sum of 2 quarters · filed 2019-10-31 | $16.79M derived: sum of 3 quarters · filed 2019-10-31 | $20.41M 10-K · filed 2019-02-13 |
| 2018-09-30 | $6.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $9.47M derived: sum of 2 quarters · filed 2019-10-31 | $13.09M 10-Q · filed 2019-10-31 | $17.24M derived: sum of 4 quarters · filed 2019-10-31 |
| 2018-06-30 | $3.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $6.93M 10-Q · filed 2019-08-01 | $11.08M derived: sum of 3 quarters · filed 2019-08-01 | $12.74M derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-03-31 | $3.62M 10-Q · filed 2019-05-01 | $7.77M derived: sum of 2 quarters · filed 2019-05-01 | $9.43M derived: sum of 3 quarters · filed 2019-05-01 | $15.12M derived: sum of 4 quarters · filed 2019-05-01 |
| 2017-12-31 | $4.15M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $5.81M derived: sum of 2 quarters · filed 2019-02-13 | $11.51M derived: sum of 3 quarters · filed 2019-02-13 | $15.29M 10-K · filed 2019-02-13 |
| 2017-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $7.35M derived: sum of 2 quarters · filed 2018-10-25 | $11.14M 10-Q · filed 2018-10-25 | $11.14M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-06-30 | $5.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $9.48M 10-Q · filed 2018-07-26 | $9.48M derived: sum of 3 quarters · filed 2019-02-13 | $9.48M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | $3.79M 10-Q · filed 2018-04-27 | $3.79M derived: sum of 2 quarters · filed 2019-02-13 | $3.79M derived: sum of 3 quarters · filed 2019-02-13 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $0.00 derived: sum of 2 quarters · filed 2019-02-13 | $0.00 10-K · filed 2019-02-13 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $0.00 10-Q · filed 2017-10-30 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-07-28 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-15 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $0.00 derived: sum of 2 quarters · filed 2016-02-16 | $0.00 10-K · filed 2016-02-16 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | ||
| 2014-06-30 | $0.00 10-Q · filed 2014-07-31 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $5.30M derived: sum of 2 quarters · filed 2016-02-16 | $10.40M derived: sum of 3 quarters · filed 2016-02-16 | $10.36M 10-K · filed 2016-02-16 |
| 2013-09-30 | $5.30M 10-Q · filed 2013-11-07 | $10.40M derived: sum of 2 quarters · filed 2013-11-07 | $10.36M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | $5.10M 10-Q · filed 2013-08-02 | $5.08M 10-Q · filed 2014-07-31 | ||
| 2012-12-31 | $55.20M 10-K · filed 2013-03-01 | $55.20M derived: sum of 2 quarters · filed 2013-11-07 | $133.20M derived: sum of 3 quarters · filed 2013-11-07 | $133.19M 10-K · filed 2015-02-13 |
| 2012-09-30 | $0.00 10-Q · filed 2013-11-07 | $78.00M derived: sum of 2 quarters · filed 2013-11-07 | $78.00M 10-Q · filed 2013-11-07 | |
| 2012-06-30 | $78.00M 10-Q · filed 2013-08-02 | $78.00M 10-Q · filed 2013-08-02 | ||
| 2011-12-31 | $0.00 10-K · filed 2014-02-11 | |||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |